Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Iovance Biotherapeutics, Inc. (IOVA) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Iovance Biotherapeutics, Inc. (IOVA) lobbying for?
Summary of the lobbying data:
– Lobbying firms hired: W Strategies, Avenue Solutions, Inc., Llc, Iovance Biotherapeutics
– General issues they lobbied on: Medicare/Medicaid, Health Issues
– Specific issues they lobbied on: including H.R. 3, Education around TIL cancer therapies., General Medicare / Medicaid Reimbursement., Education around TIL cancer therapies. 21st Century Cures 2.0. Reauthorization of the Prescription Drug User Fee Act and related issues., Build Better Back; Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, General Food and Drug Administration Issues. User Fee Reauthorization. Budget Reconciliation., Affordable Insulin Now Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, including accelerated approval and reimportation; Issues related to the Public Health Emergency; Issues related to the White House Cancer Moonshot initiative; Issues related to accelerated approval; CMS Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Rates Proposed Rule for FY 2023; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs, Education around tumor infiltrating lymphocytes (TIL) cancer therapies; S. 3700/H.R. 6833, Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; Issues related to accelerated approval; Issues related to the FY 2023 Presidents Budget; CMS Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Rates Proposed Rule for FY 2023; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; Senate Finance Committee bipartisan Discussion Draft: Ensuring Access to Telemental Health Services; Senate Finance Committee bipartisan Discussion Draft: Improving Access to Physical and Mental Health Care for Children and Youth under Medicaid and CHIP; Bipartisan Safer Communities Act, Restoring Hope for Menta
– Government agencies they lobbied: Senate, Centers For Medicare and Medicaid Services (CMS), House of Representatives
One could infer that Iovance Biotherapeutics, Inc. is lobbying on Medicare/Medicaid and Health Issues-related issues as they could potentially impact the company’s business operations and/or finances. The specific issues they lobbied on, such as H.R. 3, Education around TIL cancer therapies, and reauthorization of FDA user fee bills, suggest that the company is trying to influence healthcare policies, regulations, and funding that affect their research and development of cancer therapies, as well as access to and affordability of their products. The company also appears to be advocating for legislation that could help them expand their market and increase revenue, including making ACA tax credits/subsidies permanent and addressing the high cost of prescription drugs.
